Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated Allogeneic NK Cells for Sarcomas in Children, Adolescents and Young Adults
2024-513431-25-00Phase 2Authorised
- Sponsor
- Hospital Universitario La Paz
- Start
- Apr 2024
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic peripheral blood-derived CD56+ natural killer cells in Bone and soft tissue sarcoma, sponsored by Hospital Universitario La Paz. Primary endpoint: Toxicity (Phase I/II primary endpoint). Planned start Apr 2024; status: authorised.
02
Drugs
allogeneic peripheral blood-derived CD56+ natural killer cells
03
Conditions
Bone and soft tissue sarcoma
Beyond the preview
Go deeper on 2024-513431-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513431-25-00.